Celgene Corporation (CELG) Holdings Cut by Morse Asset Management Inc

Morse Asset Management Inc trimmed its position in shares of Celgene Corporation (NASDAQ:CELG) by 3.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,060 shares of the biopharmaceutical company’s stock after selling 2,390 shares during the quarter. Celgene Corporation accounts for approximately 2.5% of Morse Asset Management Inc’s portfolio, making the stock its 6th largest holding. Morse Asset Management Inc’s holdings in Celgene Corporation were worth $7,800,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Neuberger Berman Group LLC boosted its holdings in Celgene Corporation by 4.0% during the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after acquiring an additional 71,729 shares during the last quarter. Lincoln Capital Corp boosted its holdings in Celgene Corporation by 0.6% during the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after acquiring an additional 185 shares during the last quarter. Swiss National Bank boosted its holdings in Celgene Corporation by 27.2% during the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock worth $341,796,000 after acquiring an additional 588,000 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Celgene Corporation by 9.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after acquiring an additional 54,210 shares during the last quarter. Finally, Iguana Healthcare Management LLC boosted its holdings in Celgene Corporation by 12.5% during the 1st quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock worth $11,199,000 after acquiring an additional 10,000 shares during the last quarter. 79.36% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Celgene Corporation (CELG) Holdings Cut by Morse Asset Management Inc” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://ledgergazette.com/2017/10/09/celgene-corporation-celg-holdings-cut-by-morse-asset-management-inc.html.

In other Celgene Corporation news, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the transaction, the director now directly owns 76,301 shares in the company, valued at $10,264,010.52. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock worth $6,268,259 over the last three months. Insiders own 0.95% of the company’s stock.

Shares of Celgene Corporation (CELG) opened at 139.21 on Monday. The company has a 50-day moving average price of $139.31 and a 200-day moving average price of $129.53. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $147.17. The company has a market capitalization of $108.91 billion, a PE ratio of 43.11 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same period last year, the firm posted $1.44 earnings per share. Analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.

A number of equities research analysts have recently commented on the company. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $175.00 target price on shares of Celgene Corporation in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated a “buy” rating and set a $173.00 target price on shares of Celgene Corporation in a research note on Thursday. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 target price on shares of Celgene Corporation in a research note on Tuesday, September 26th

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Neuberger Berman Group LLC boosted its holdings in Celgene Corporation by 4.0% during the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after acquiring an additional 71,729 shares during the last quarter. Lincoln Capital Corp boosted its holdings in Celgene Corporation by 0.6% during the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after acquiring an additional 185 shares during the last quarter. Swiss National Bank boosted its holdings in Celgene Corporation by 27.2% during the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock worth $341,796,000 after acquiring an additional 588,000 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Celgene Corporation by 9.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after acquiring an additional 54,210 shares during the last quarter. Finally, Iguana Healthcare Management LLC boosted its holdings in Celgene Corporation by 12.5% during the 1st quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock worth $11,199,000 after acquiring an additional 10,000 shares during the last quarter. 79.36% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Celgene Corporation (CELG) Holdings Cut by Morse Asset Management Inc” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://ledgergazette.com/2017/10/09/celgene-corporation-celg-holdings-cut-by-morse-asset-management-inc.html.

In other Celgene Corporation news, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the transaction, the director now directly owns 76,301 shares in the company, valued at $10,264,010.52. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock worth $6,268,259 over the last three months. Insiders own 0.95% of the company’s stock.

Shares of Celgene Corporation (CELG) opened at 139.21 on Monday. The company has a 50-day moving average price of $139.31 and a 200-day moving average price of $129.53. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $147.17. The company has a market capitalization of $108.91 billion, a PE ratio of 43.11 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same period last year, the firm posted $1.44 earnings per share. Analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.

A number of equities research analysts have recently commented on the company. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $175.00 target price on shares of Celgene Corporation in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated a “buy” rating and set a $173.00 target price on shares of Celgene Corporation in a research note on Thursday. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 target price on shares of Celgene Corporation in a research note on Tuesday, September 26th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a research note on Wednesday, August 16th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $150.00 target price on shares of Celgene Corporation in a research note on Friday, July 14th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and twenty-two have issued a buy rating to the company. Celgene Corporation currently has a consensus rating of “Buy” and an average target price of $150.60.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply